NUSINERSEN (SPINRAZA) prior authorization at Elevance Health
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
The PA criteria you'll need to meet
Elevance Health reviews NUSINERSEN (SPINRAZA) prior authorizations against its medical policy for Survival Motor Neuron-2-directed RNA Interaction [EPC]. The FDA-approved indication (2016) is SOLUTION. Elevance Health-specific context: Operates Anthem BCBS in 14 states. Owns Carelon (formerly AIM) which manages utilization for specialty drugs and advanced imaging. State complaint route is to the state insurance department where the policy was issued.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Survival Motor Neuron-2-directed RNA Interaction [EPC]
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Elevance Health's medical policy URL referenced in the cover letter
Elevance Health's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Step therapy
- Medical necessity for biologics
- Out-of-network for behavioral health
- Bariatric surgery prior auth
If the PA is denied
Elevance Health gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://providers.anthem.com) with the same packet plus a peer-reviewed citation supporting NUSINERSEN (SPINRAZA)for the patient's indication.
Contact Elevance Health
- Provider portal: https://providers.anthem.com
Frequently asked questions
What documentation does Elevance Health need for NUSINERSEN (SPINRAZA) prior auth?
Elevance Health's typical PA packet for NUSINERSEN (SPINRAZA): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Survival Motor Neuron-2-directed RNA Interaction [EPC], expect clinical-criteria documentation specific to this class.
What's the turnaround time at Elevance Health?
Standard NUSINERSEN (SPINRAZA) PA decisions at Elevance Health: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Elevance Health most often reject NUSINERSEN (SPINRAZA) for?
Across Elevance Health's book the common rejection patterns include: Step therapy; Medical necessity for biologics; Out-of-network for behavioral health. For NUSINERSEN (SPINRAZA) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with Elevance Health on NUSINERSEN (SPINRAZA)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Generate the NUSINERSEN (SPINRAZA) PA packet
Open ApprovalHelp — generate a NUSINERSEN (SPINRAZA) prior-auth packet tailored to Elevance Health's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com